SCHEMBL20935160

SCHEMBL20935160

CC(C)(C)C(=O)[C@H](CCCNC(N)=O)NC(=O)[C@H](CC(=O)O)NC(=O)CCCCCN1C(=O)CCC1=O

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ SMN1; SMN2 Q16637 2/20 0.41
▸ HTT P42858 2/20 0.41
▸ HPGD P15428 2/20 0.41
▸ ALDH1A1 P00352 2/20 0.38
▸ PKM P14618 1/20 0.37
▸ ITGB3 P05106 2/20 0.36
▸ ITGA2B P08514 2/20 0.36
▸ HSD17B10 Q99714 2/20 0.36
▸ KDM4E B2RXH2 1/20 0.36
▸ GAA P10253 1/20 0.36
▸ PTPN1 P18031 2/20 0.36
▸ LMNA P02545 1/20 0.35
▸ NPY4R P50391 2/20 0.35
▸ TSHR P16473 1/20 0.35
▸ MAPT P10636 1/20 0.35
▸ ALPL P05186 1/20 0.35
▸ POLB P06746 1/20 0.35
▸ NPY1R P25929 1/20 0.34
▸ NPY2R P49146 1/20 0.34
▸ NPY5R Q15761 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22668929 0.90 PTGS1 (0.44) ITGB3ITGA2BPTPN1NPY4RNPY1R
SCHEMBL20340675 0.80 NMT1 (0.43) NPY4RNPY1RNPY2RNPY5RNMT2
SCHEMBL22668934 0.80 NPY4R (0.38) NPY4RNPY1RNPY2RNPY5RNMT2
SCHEMBL18932741 0.79 PTGS1 (0.46) ITGB3ITGA2BPTPN1NPY4RNPY1R
SCHEMBL17722910 0.79 PTGS1 (0.46) ITGB3ITGA2BPTPN1NPY4RNPY1R
SCHEMBL23436462 0.79 NMT1 (0.46) NPY4RNPY1RNPY2RNPY5RNMT2
SCHEMBL20889000 0.79 NMT1 (0.46) NPY4RNPY1RNPY2RNPY5RNMT2
SCHEMBL22184191 0.78 SMN1; SMN2 (0.43) SMN1; SMN2HTTHPGDALDH1A1POLB
SCHEMBL20889018 0.78 PTGS1 (0.45) ITGB3ITGA2BPTPN1NPY4RNPY1R
SCHEMBL21474404 0.78 PTGS1 (0.45) ITGB3ITGA2BPTPN1NPY4RNPY1R

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11161911-B2 Anti-glyco-MUC1 antibodies and their uses GO THERAPEUTICS, INC. (US) 2021-11-02 — — US disclosed
US-20190119400-A1 ANTI-GLYCO-MUC1 ANTIBODIES AND THEIR USES GO THERAPEUTICS, INC. (US) 2019-04-25 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11161911-B2 Anti-glyco-MUC1 antibodies and their uses MUC1, SIGLEC7, SIGLEC9 SMN1; SMN2 4252/4885HTT 3210/4885HPGD 4338/4885
US-20190119400-A1 ANTI-GLYCO-MUC1 ANTIBODIES AND THEIR USES MUC1, SIGLEC7, SIGLEC9 SMN1; SMN2 4252/4885HTT 3210/4885HPGD 4338/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback